Trials / Completed
CompletedNCT02516111
Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment
Comparative Evaluation of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Treatment of 2/3-walled Intrabony Defects in Chronic Periodontitis Subjects: a Randomized Controlled Clinical Trial
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Government Dental College and Research Institute, Bangalore · Academic / Other
- Sex
- Female
- Age
- 30 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The present study is designed as a single-centre, randomized, controlled clinical trial to evaluate and compare the clinical efficacy of autologous PRF, 1% alendronate (ALN) and 1.2% atorvastatin (ATV) gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis.
Detailed description
Background: Platelet-rich fibrin (PRF) is a second-generation platelet concentrate which releases various growth factors that promote tissue regeneration. Alendronate and Atorvastatin are known to inhibit osteoclastic bone resorption and were proposed to have osteostimulative properties by causing osteoblast differentiation in vivo and in vitro as shown by an increase in matrix formation. The aim of the present study is to evaluate and compare the efficacy of autologous PRF, 1% alendronate and 1.2% atorvastatin gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis. Methods: 120 CP subjects with IBD ≥3 mm deep and probing depth (PD) ≥5 mm, following scaling and root planing (SRP), were categorized into four treatment groups: 1) OFD 2) OFD with PRF 3) OFD with 1% ALN gel and 4) OFD with 1.2% ATV gel. Clinical parameters including site specific plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD) and relative attachment level (RAL) as well as percentage radiographic intrabony defect depth reduction (DDR) were recorded at baseline before surgery and 9 months post-operatively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Open flap debridement (OFD) | Oral prophylaxis followed by Open flap debridement (OFD) |
| BIOLOGICAL | OFD with PRF | Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect |
| DRUG | OFD with ALN | Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect |
| DRUG | OFD with ATV | Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2015-08-05
- Last updated
- 2015-08-05
Source: ClinicalTrials.gov record NCT02516111. Inclusion in this directory is not an endorsement.